Janux Therapeutics (JANX) EBIT Margin: 2020-2025
Historic EBIT Margin for Janux Therapeutics (JANX) over the last 4 years, with Sep 2025 value amounting to -352.51%.
- Janux Therapeutics' EBIT Margin rose 781195.00% to -352.51% in Q3 2025 from the same period last year, while for Sep 2025 it was -700.84%, marking a year-over-year decrease of 4207.00%. This contributed to the annual value of -933.58% for FY2024, which is 3071.00% down from last year.
- Latest data reveals that Janux Therapeutics reported EBIT Margin of -352.51% as of Q3 2025, which was up 95.68% from -8,164.46% recorded in Q3 2024.
- Over the past 5 years, Janux Therapeutics' EBIT Margin peaked at -155.36% during Q2 2024, and registered a low of -8,164.46% during Q3 2024.
- Moreover, its 3-year median value for EBIT Margin was -823.00% (2023), whereas its average is -1,814.97%.
- Per our database at Business Quant, Janux Therapeutics' EBIT Margin tumbled by 753,622bps in 2024 and then surged by 781,195bps in 2025.
- Janux Therapeutics' EBIT Margin (Quarterly) stood at -834.78% in 2021, then spiked by 19,274bps to -642.04% in 2022, then slumped by 1,367bps to -655.71% in 2023, then crashed by 753,622bps to -8,164.46% in 2024, then skyrocketed by 781,195bps to -352.51% in 2025.
- Its EBIT Margin was -352.51% in Q3 2025, compared to -8,164.46% in Q3 2024 and -155.36% in Q2 2024.